Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07451171
PHASE2

Comparative Efficacy of Antibiotics for Small Intestine Bacterial Overgrowth in Bangladeshi Children

Sponsor: University of Virginia

View on ClinicalTrials.gov

Summary

The purpose of this Phase IIa study is to identify the most effective antibiotic regimen to treat small intestine bacterial overgrowth (SIBO) in impoverished Bangladeshi children.

Official title: A Phase II Trial to Prevent Linear Growth Stunting and Malnutrition in Impoverished Children From a Low-Income Country by Treating Small Intestine Bacterial Overgrowth

Key Details

Gender

All

Age Range

1 Year - 2 Years

Study Type

INTERVENTIONAL

Enrollment

60

Start Date

2026-04

Completion Date

2026-06

Last Updated

2026-03-05

Healthy Volunteers

No

Interventions

DRUG

Trimethoprim-sulfamethoxazole (TMP/SMX)

8-10 mg/kg/day divided every 12 hours, with a maximum 160 mg/dose; dosing based on Trimethoprim

DRUG

Metronidazole

Administered alone: 20-30 mg/kg/day divided every 8 hours, with a maximum 750 mg/dose Co-administered with Trimethoprim-sulfamethoxazole: 35-50 mg/kg/day divided every 8 hours, with a maximum 750 mg/dose

DRUG

Amoxicillin-Clavulanate (4:1 formulation)

20-40 mg amoxicillin/kg/day divided every 8 hours, with maximum daily dose of 1,500 mg

Locations (1)

International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b)

Dhaka, Bangladesh